No Data
Chun Sheng Group-B (06628.HK): Announced at the ESMO 2024 Congress, the latest business progress of OSEMITAMAB (TST001) triplet therapy for the first-line treatment of inspiring efficacy data for gastric or gastroesophageal junction adenocarcinoma.
On September 19th, Changsheng Group-B (06628.HK) announced updated research data on the G-queue for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (TranStar102) using Osemitamab (TST001) in combination with Narulitinib and CAPOX. The data from this queue has consistently shown encouraging efficacy since its announcement at the ASCO 2024 conference. The study results showed that in patients with known levels of CLDN18.2 and PD-L1 expression, patients with high/medium expression of CLDN18.2 had a median progression-free survival (mPFS).
TRANSCENTA-B: 2024 INTERIM REPORT
On September 10th, Chong Sheng Group-B (06628.HK) spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
GlueNet September 10th, Creatilon Group-B (06628.HK) announced that on September 10th, it spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
Chuangsheng Group - B [06628] is currently trading at HKD 1.13, with a decrease of 11.72%.
As of 15:28, China Winner Group - B [06628] reported HK$1.13, down HK$0.15 or 11.72% from yesterday's closing price of HK$1.28. The trading volume was HK$0.0188 million. The highest price today was HK$1.25 and the lowest price was HK$1.13. Based on yesterday's closing price, the 10-day average price was HK$1.81 and the 50-day average price was HK$1.83. The current P/E ratio is -1.41 times and the 14-day strength index is 31.25.
Chuangsheng Group-B (06628.HK) cancelled 2.14 million shares on August 29th.
Gelonghui August 29th | Chuangsheng Group-B (06628.HK) announced that on August 29, 2024, the company cancelled 2.14 million shares repurchased.
Chuangsheng Group B (06628) issued 2.1996 million shares under the stock-based incentive plan.
Chuangsheng Group-B (06628) announced that it will issue shares in accordance with the company's stock-based incentive plan on August 29, 2024...
No Data
No Data
